x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243239
| Product Information | |
|---|---|
| CAS No. | 1868138-66-2 |
| Synonyms | HTD1801; BUDCA |
| Formula | C44H57NO8 |
| Molecular Weight | 727.93 |
| SMILES | COC1=C2C=[N+]3C(C4=CC(OCO5)=C5C=C4CC3)=CC2=CC=C1OC.C[C@@]67[C@](CC[C@]7([H])[C@H](C)CCC([O-])=O)([H])[C@@]8([H])[C@@](CC6)([H])[C@@]9([C@](C[C@@H](CC9)O)([H])C[C@@H]8O)C |
| Target | Others |
| Product Description | Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | Light yellow to yellow |
| Purity | 98.75% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
